APTOF
Aptose Biosciences Inc NASDAQ NMS - GLOBAL$1.73
Mkt Cap $4.4M
52w Low $1.51
22.9% of range
52w High $2.47
P/E (TTM)
-0.2x
EV/EBITDA
—
P/B
—
Debt/Equity
0.0x
ROE
93.8%
P/FCF
—
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
—
200d MA
—
Avg Volume
3.5K
Recent Filings
8-K · 7.01
! Medium
Aptose Biosciences Inc -- 8-K 7.01: Regulation FD Disclosure
Aptose Biosciences issued a press release on April 30, 2026, disclosed under Regulation FD, which is not considered an official SEC filing for liability purposes.
Apr 30
8-K
Unknown — 8-K Filing
Unable to provide analysis—the filing lacks substantive business information; it appears to be a technical XBRL schema document rather than a meaningful company disclosure.
Mar 31
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Hanmi Pharmaceutical's acquisition of Aptose eliminates public market access to the company's promising AML therapy pipeline, but investors lose upside potential if the TUS+VEN+AZA triplet achieves blockbuster success post-acquisition.
Mar 31
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Glass Lewis's recommendation on an upcoming Aptose shareholder vote could significantly influence deal outcomes or governance decisions, making the voting deadline critical for investors to monitor potential ownership changes or strategic pivots.
Mar 23
8-K
Unknown — 8-K Filing
This 8-K reveals an amendment to the CEO's employment agreement, signaling potential changes to executive compensation, benefits, or severance terms that could affect shareholder value and future earnings guidance.
Mar 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ISS's recommendation to vote FOR Hanmi's acquisition of Aptose increases deal certainty and likely supports the stock price at or near the agreed acquisition price, benefiting shareholders seeking transaction closure.
Mar 19
Data updated apr 28, 2026 1:43am
· Source: massive.com